Catalyst Dossier · compiled by Celia 🧫

Roche Holding AG (RHHBY)

Biotechnology · market cap $316.4B · as of 2026-06-23

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-06-30 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Roche Holding AG (RHHBY) is a large-cap Swiss pharmaceutical and diagnostics conglomerate with 103,249 employees and a market capitalization of approximately $316 billion. The company operates an extensive late-stage pipeline spanning oncology, neurology, immunology, and rare disease, with near-term catalysts concentrated in mid-2026 across multiple Phase 2 and Phase 3 readouts. The lead novel asset flagged in this dossier is RO7239361 in Phase 3 for Duchenne Muscular Dystrophy, alongside RO7204239 in Phase 3 for obesity and a broad set of additional pipeline programs.

The catalyst path

2026-06-30 (est.)Phase 2 · Entrectinibimp 7/10
2026-06-30 (est.)Phase 3 · Tociluzumabimp 9/10
2026-07-13 (est.)Phase 2 · peginterferon alfa-2a [Pegasys]imp 7/10
2026-07-22 (est.)Phase 2 · Afimkibartimp 7/10
2026-07-31 (est.)Phase 2 · Tobemstomigimp 7/10
2026-08-24 (est.)Phase 2 · RO7204239imp 7/10
2026-08-26 (est.)Phase 2 · satralizumabimp 7/10
2026-08-28 (est.)Phase 2 · Giredestrantimp 7/10

Pipeline

Asset	Phase	Indication
RO7239361	Phase 3	Duchenne Muscular Dystrophy
RO7204239	Phase 3	Obesity
trastuzumab (Herceptin®)	Phase 3	Breast Cancer
mycophenolate mofetil [CellCept]	Phase 3	Myasthenia Gravis Generalised
Lenvatinib	Phase 3	Unresectable Hepatocellular Carcinoma
Eculizumab	Phase 3	Paroxysmal Nocturnal Hemoglobinuria
Dual Integrin Antagonist	Phase 2	Asthma
RO4917523 1.5 mg	Phase 2	Major Depressive Disorder
5 FU	Phase 3	Neoplasms
Atezolizumab Cohort 7	Phase 2	Solid Tumors
boceprevir	Phase 2	Hepatitis C, Chronic
Abemaciclib	Phase 2	Ovarian Cancer
Intravitreal Ranibizumab 0.5 mg Injection	Phase 3	Diabetic Macular Edema
Treatment of physician's choice	Phase 3	Breast Cancer
Oxaliplatin	Phase 3	Colorectal Cancer
Ro 24-7429	Phase 2	Sarcoma, Kaposi
montelukast [Singulair]	Phase 3	Asthma
Non-Biologic DMARDs	Phase 3	Rheumatoid Arthritis
rHuPH20	Phase 3	Non-Small Cell Lung Cancer
Tociluzumab	Phase 3	Relapsed or Refractory Follicular Lymphoma

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by Celia. The catalyst path & pipeline above are free.

See Pro

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by Celia. Not financial advice.